UNSPSC 51272903: Fospropofol sodium

This classification denotes an anesthetic agent with the molecular formula C13H19O5P.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 30868AY0IF, chemically known as methanol, (2,6-bis(1-methylethyl)phenoxy)-, dihydrogen phosphate, disodium salt but more generally known as fospropofol disodium, which bears US NIH Compound Identifier 3038497. European Medicines Agency schedules Fospropofol disodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32986.

Most nations, for tariff and trade purposes, schedule fospropofol sodium under HS 29199000 and SITC 51631. SMILES: CC(C)C1CCCC(C1OCOP(=O)([O-])[O-])C(C)C.[NA+].[NA+].

UNSPSC 51272903 Fospropofol sodium is a Commodity code that in practice captures procurement of pharmaceutical products and related medical supply systems by state and local health agencies, though recent state and local solicitations tagged to this code show minimal direct activity for fospropofol itself. Instead, the opportunities reflect broader pharmaceutical and OTC product procurement by health departments, county community health systems, and multistate cooperative purchasing alliances sourcing generic drugs, naloxone products, and drug deactivation systems to support public health initiatives and pharmacy benefit programs. The issuing bodies span state health and human services departments, county health authorities, and cooperative purchasing vehicles that aggregate demand across multiple jurisdictions. Vendors typically supply through authorized pharmaceutical wholesalers, must maintain cGMP and Drug Supply Chain Security Act compliance, and are subject to detailed product specification requirements including National Drug Codes, packaging configurations, and shelf-life certifications.

Recent activity appears concentrated in Texas and Minnesota through multistate cooperative vehicles and targeted county initiatives. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to explore direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 in January 2026 (response due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with contract effectiveness July 1, 2026. In Florida, Seminole County posted IFB 60459723LAS in June 2026 (response due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with a two-year initial term and one-year renewal option. MMCAP contracts emphasize price competitiveness (75 percent evaluation weight), wholesaler relationship requirements, and performance penalties for reporting or onboarding delays, while county-level procurements stress local delivery logistics and standard commercial insurance coverages.